vs
BICYCLE THERAPEUTICS PLC（BCYC）与CENTERSPACE（CSR）财务数据对比。点击上方公司名可切换其他公司
CENTERSPACE的季度营收约是BICYCLE THERAPEUTICS PLC的1.4倍（$65.1M vs $48.0M），CENTERSPACE净利率更高（-23.0% vs -42.0%，领先19.0%），BICYCLE THERAPEUTICS PLC同比增速更快（1193.3% vs -3.0%），过去两年BICYCLE THERAPEUTICS PLC的营收复合增速更高（56.7% vs 0.0%）
Bicycle Therapeutics是一家临床阶段生物制药企业，专注于开发双环肽类创新疗法以解决未被满足的医疗需求，核心管线覆盖肿瘤、罕见病与免疫疾病领域，在欧美布局运营，与全球头部药企达成战略合作推进候选药物落地。
Centerspace是一家专注于多户住宅物业持有、运营与开发的房地产投资企业，核心业务覆盖美国中西部及落基山西部区域，面向不同租户群体提供经济型及高端住宅选择，重视租户体验与资产长期价值增长。
BCYC vs CSR — 直观对比
营收规模更大
CSR
是对方的1.4倍
$48.0M
营收增速更快
BCYC
高出1196.3%
-3.0%
净利率更高
CSR
高出19.0%
-42.0%
两年增速更快
BCYC
近两年复合增速
0.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $48.0M | $65.1M |
| 净利润 | $-20.2M | $-15.0M |
| 毛利率 | — | — |
| 营业利润率 | -51.5% | — |
| 净利率 | -42.0% | -23.0% |
| 营收同比 | 1193.3% | -3.0% |
| 净利润同比 | 61.1% | -258.1% |
| 每股收益（稀释后） | $-0.29 | $-0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCYCCSR
| Q1 26 | — | $65.1M | ||
| Q4 25 | $48.0M | $66.6M | ||
| Q3 25 | $11.7M | $71.4M | ||
| Q2 25 | $2.9M | $68.5M | ||
| Q1 25 | $10.0M | $67.1M | ||
| Q4 24 | $3.7M | $66.4M | ||
| Q3 24 | $2.7M | $65.0M | ||
| Q2 24 | $9.4M | $65.0M |
净利润BCYCCSR
| Q1 26 | — | $-15.0M | ||
| Q4 25 | $-20.2M | $-18.4M | ||
| Q3 25 | $-59.1M | $53.8M | ||
| Q2 25 | $-79.0M | $-14.5M | ||
| Q1 25 | $-60.8M | $-3.7M | ||
| Q4 24 | — | $-5.1M | ||
| Q3 24 | $-50.8M | $-1.0M | ||
| Q2 24 | $-39.8M | $-1.3M |
毛利率BCYCCSR
| Q1 26 | — | — | ||
| Q4 25 | — | 96.5% | ||
| Q3 25 | — | 96.5% | ||
| Q2 25 | — | 96.5% | ||
| Q1 25 | — | 96.4% | ||
| Q4 24 | — | 96.5% | ||
| Q3 24 | — | 96.6% | ||
| Q2 24 | — | 96.6% |
营业利润率BCYCCSR
| Q1 26 | — | — | ||
| Q4 25 | -51.5% | -15.9% | ||
| Q3 25 | -558.6% | — | ||
| Q2 25 | -2965.8% | -9.9% | ||
| Q1 25 | -703.7% | 7.1% | ||
| Q4 24 | — | 4.3% | ||
| Q3 24 | -2385.9% | 9.8% | ||
| Q2 24 | -498.3% | 11.1% |
净利率BCYCCSR
| Q1 26 | — | -23.0% | ||
| Q4 25 | -42.0% | -27.7% | ||
| Q3 25 | -503.7% | 75.3% | ||
| Q2 25 | -2703.8% | -21.2% | ||
| Q1 25 | -608.9% | -5.6% | ||
| Q4 24 | — | -7.6% | ||
| Q3 24 | -1898.4% | -1.6% | ||
| Q2 24 | -425.3% | -2.0% |
每股收益（稀释后）BCYCCSR
| Q1 26 | — | $-0.49 | ||
| Q4 25 | $-0.29 | $-1.08 | ||
| Q3 25 | $-0.85 | $3.19 | ||
| Q2 25 | $-1.14 | $-0.87 | ||
| Q1 25 | $-0.88 | $-0.22 | ||
| Q4 24 | — | $-0.31 | ||
| Q3 24 | $-0.74 | $-0.40 | ||
| Q2 24 | $-0.77 | $-0.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $628.1M | $7.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $610.0M | $695.0M |
| 总资产 | $717.6M | $1.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCYCCSR
| Q1 26 | — | $7.6M | ||
| Q4 25 | $628.1M | $12.8M | ||
| Q3 25 | $648.3M | $12.9M | ||
| Q2 25 | $721.5M | $12.4M | ||
| Q1 25 | $793.0M | $11.9M | ||
| Q4 24 | $879.5M | $12.0M | ||
| Q3 24 | $890.9M | $14.5M | ||
| Q2 24 | $961.4M | $14.3M |
总债务BCYCCSR
| Q1 26 | — | — | ||
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $955.5M | ||
| Q4 24 | — | $955.4M | ||
| Q3 24 | — | $921.3M | ||
| Q2 24 | $30.9M | $931.7M |
股东权益BCYCCSR
| Q1 26 | — | $695.0M | ||
| Q4 25 | $610.0M | $719.2M | ||
| Q3 25 | $618.5M | $748.6M | ||
| Q2 25 | $668.9M | $710.1M | ||
| Q1 25 | $740.3M | $636.8M | ||
| Q4 24 | $793.1M | $752.0M | ||
| Q3 24 | $831.0M | $672.5M | ||
| Q2 24 | $873.8M | $680.7M |
总资产BCYCCSR
| Q1 26 | — | $1.9B | ||
| Q4 25 | $717.6M | $1.9B | ||
| Q3 25 | $764.0M | $2.1B | ||
| Q2 25 | $832.2M | $2.0B | ||
| Q1 25 | $883.9M | $1.9B | ||
| Q4 24 | $956.9M | $1.9B | ||
| Q3 24 | $996.7M | $1.9B | ||
| Q2 24 | $1.1B | $1.9B |
负债/权益比BCYCCSR
| Q1 26 | — | — | ||
| Q4 25 | — | 1.42× | ||
| Q3 25 | — | 1.53× | ||
| Q2 25 | — | 1.57× | ||
| Q1 25 | — | 1.50× | ||
| Q4 24 | — | 1.27× | ||
| Q3 24 | — | 1.37× | ||
| Q2 24 | 0.04× | 1.37× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-19.3M | — |
| 自由现金流经营现金流 - 资本支出 | $-19.9M | — |
| 自由现金流率自由现金流/营收 | -41.5% | — |
| 资本支出强度资本支出/营收 | 1.2% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-252.0M | — |
8季度趋势，按日历期对齐
经营现金流BCYCCSR
| Q1 26 | — | — | ||
| Q4 25 | $-19.3M | $98.5M | ||
| Q3 25 | $-71.2M | $35.1M | ||
| Q2 25 | $-72.8M | $25.3M | ||
| Q1 25 | $-86.4M | $25.4M | ||
| Q4 24 | $-164.7M | $98.2M | ||
| Q3 24 | $-39.8M | $32.3M | ||
| Q2 24 | $-44.6M | $22.9M |
自由现金流BCYCCSR
| Q1 26 | — | — | ||
| Q4 25 | $-19.9M | $64.3M | ||
| Q3 25 | $-71.8M | $25.7M | ||
| Q2 25 | $-73.3M | $15.5M | ||
| Q1 25 | $-87.0M | $20.4M | ||
| Q4 24 | $-166.0M | $41.6M | ||
| Q3 24 | $-40.3M | $20.5M | ||
| Q2 24 | $-45.0M | $9.1M |
自由现金流率BCYCCSR
| Q1 26 | — | — | ||
| Q4 25 | -41.5% | 96.5% | ||
| Q3 25 | -612.3% | 36.0% | ||
| Q2 25 | -2509.7% | 22.7% | ||
| Q1 25 | -871.7% | 30.4% | ||
| Q4 24 | -4475.7% | 62.6% | ||
| Q3 24 | -1504.7% | 31.5% | ||
| Q2 24 | -481.2% | 14.0% |
资本支出强度BCYCCSR
| Q1 26 | — | 0.3% | ||
| Q4 25 | 1.2% | 51.3% | ||
| Q3 25 | 5.7% | 13.1% | ||
| Q2 25 | 17.1% | 14.2% | ||
| Q1 25 | 6.1% | 7.5% | ||
| Q4 24 | 33.3% | 85.3% | ||
| Q3 24 | 16.3% | 18.2% | ||
| Q2 24 | 4.5% | 21.2% |
现金转化率BCYCCSR
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
